Inpatient Hypertension: Treatment vs. Watchful Waiting
RSV Vaccine Approved for Older Adults: A Breakthrough in Respiratory Protection
Understanding RSV and Why It’s a Threat to Seniors
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. However, for older adults, RSV can lead to severe illness, including pneumonia and hospitalization. Before the development of a vaccine,RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years and older in the United States. The virus weakens the respiratory system, making individuals more vulnerable to secondary infections.
The increased risk for seniors stems from age-related decline in immune function and the presence of underlying health conditions like heart failure and chronic obstructive pulmonary disease (COPD). These factors compromise the body’s ability to fight off the virus effectively.
The Arexvy Vaccine: how It Works and Trial Results
Arexvy, developed by GSK, is a recombinant subunit vaccine containing a stabilized prefusion F protein. This protein is found on the surface of the RSV virus and is crucial for the virus to enter cells. By presenting this protein to the immune system, the vaccine triggers the production of antibodies that can neutralize the virus and prevent infection.
The pivotal Phase 3 clinical trial, involving approximately 24,636 adults aged 60 years and older, demonstrated a vaccine efficacy of 82.6% against RSV-associated lower respiratory tract disease (LRTD) with at least one symptom. Specifically, the vaccine showed 94.1% efficacy against severe LRTD, defined as illness requiring three or more symptoms. the study, published in the New England Journal of Medicine on November 20, 2025, confirmed these findings.
| Outcome | Vaccine Efficacy |
|---|---|
| RSV-associated LRTD (≥1 symptom) | 82.6% |
| Severe RSV-associated LRTD (≥3 symptoms) | 94.1% |
Importantly, the trial also assessed the safety profile of Arexvy. While some participants experienced mild to moderate side effects, such as pain at the injection site, fatigue, and muscle aches, serious adverse events were rare and not considerably different between the vaccine and placebo groups. A small increased risk of inflammatory conditions was observed, prompting ongoing monitoring.
Who Should Get the RSV Vaccine?
The FDA approved Arexvy for adults aged 60 years and older to prevent RSV-associated LRTD. The CDC’s ACIP will provide specific recommendations regarding who should *routinely* receive the vaccine. Current guidance suggests a shared clinical decision-making approach, considering individual risk factors and patient preferences. Factors influencing this decision include age, underlying health conditions, lifestyle, and prior RSV exposure.
It’s crucial to discuss vaccination with your healthcare provider to determine if Arexvy is right for you.They can assess your individual risk and provide personalized advice.
What to Expect After Vaccination
Like